Increasing funding for the healthcare system, introducing new technologies and improving the principles of healthcare provision
The main thing is increasing state funding for healthcare. Let me remind you that in 2019, before the COVID epidemic, [funding] stood at 3.5% of GDP — Guzel Ulumbekova, Head, Higher School of Healthcare Organization and Management.
It is important to acknowledge that digital medical technologies have seen significant changes. Telemedicine has progressed to a whole new level. Of course, the fact that we launched vertically integrated digital telemedicine systems and a one-stop online resource in 2018 – as well as a website for key specialists at the Ministry of Health – helped us a great deal. They actually became reference points for expert advice during the pandemic…. Of course, we adopted completely new principles in creating mobile rapid response units, including major joint detachments of the Federal Medical-Biological Agency of up to 100 people, making it possible to deal with serious epidemiological outbreaks in a very short time, around two to three days, at a number of remote enterprises and in remote regions throughout the country — Veronika Skvortsova, Head, Federal Medical-Biological Agency of the Russian Federation.
We also need to acknowledge the model of healthcare provision. We took the route of putting together instructional guidelines, and in the initial months we summarized all global best practices with the help of leading specialists from outside the ministry. We have put together everything we need in order to issue guidelines that will help doctors throughout the country deal with this threat comprehensively. That includes the use of medicines, medical devices and patient treatment methods — Victor Fisenko, First Deputy Minister of Health of the Russian Federation.
We were the first in the world to register an official booster jab, Sputnik Light. This in turn can be used to boost AstraZeneca, Moderna and Pfizer. As you know, we are manufacturing Sputnik Light in very high volumes, so our future strategy is to use it… not just to revaccinate Russians or use it as an independent vaccine, but also to offer it as a booster for AstraZeneca and other vaccines. This is not just a statement of intent: we are carrying out research in Argentina that is showing the effectiveness of these boosters — Kirill Dmitriev, Chief Executive Officer, Russian Direct Investment Fund (RDIF).